Cerus Q3 2026 net loss widens to $550,000
CERS•Cerus’ third-quarter 2026 net loss widened to $550,000, while revenue rose 6% to $64 million. Full-year product revenue guidance remained $229 million to $231 million.
1. Quarterly results
Cerus’ third-quarter net loss attributable to the company widened year-over-year to $550,000. Total revenue increased 6% to $64 million, including a 10% rise in product revenue to $57.71 million, while operating cash flow climbed 58% to $3 million. The company reported positive topline results from its Phase 3 RedeS trial of the INTERCEPT Blood System for red blood cells. Full-year 2026 product revenue guidance remained $229 million to $231 million, including $23 million to $25 million from IFC.
